Back

• Tue May 3, 2022

  AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration

  Collaboration expanded from five to seven targets and provides AbCellera the option to co-develop therapeutic programs in partnership with Empirico.

  Read More
• Wed Apr 14, 2021

  AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

  VANCOUVER, British Columbia & SAN DIEGO, April 14, 2021 — AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration.

  Read More
• Thu Jan 9, 2020

  Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeutics

  SAN DIEGO, January 9, 2020 — Empirico Inc. announced today that it has entered into a strategic collaboration with Ionis Pharmaceuticals.

  Read More